5,150€
-0,96%
Echtzeit-Aktienkurs Maravai LifeSciences Holdings Inc.
Bid:
Ask:
Echtzeit-Chart der Maravai LifeSciences Holdings Inc. Aktie
Börsenkurse Maravai LifeSciences Holdings Inc.
| Echtzeit Euro | - | - | - | - | 5,150€ | -0,96% |
| Nasdaq | - | - | - | - | 5,375$ | -1,01% |
| Echtzeit USD | - | - | - | - | 5,358$ | -1,32% |
| Tradegate | - | - | - | - | 5,150€ | -2,83% |
| Börse Stuttgart | - | - | - | - | 5,150€ | -2,83% |
| Börse Frankfurt | - | - | - | - | 5,150€ | -0,96% |
| USA | - | - | - | - | 5,375$ | -1,01% |
| Lang & Schwarz | - | - | - | - | 5,150€ | -1,90% |
Fundamentaldaten der Maravai LifeSciences Holdings Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 288,95 Mio. | 617,74 Mio. | -119,03 Mio. | -0,90 | - | - | 2,36 |
| 2022 [USD] | 883,00 Mio. | 551,47 Mio. | 220,21 Mio. | 1,67 | - | 3,08 | 0,77 |
| 2021 [USD] | 799,24 Mio. | 530,77 Mio. | 182,04 Mio. | 1,56 | - | 3,30 | 0,85 |
| 2020 [USD] | 284,10 Mio. | 81,70 Mio. | 76,89 Mio. | 0,70 | - | 7,32 | 1,75 |
| 2019 [USD] | 143,14 Mio. | -5,85 Mio. | -8,48 Mio. | -0,09 | - | - | 3,48 |
| 2018 [USD] | 123,83 Mio. | -16,50 Mio. | -17,73 Mio. | -0,18 | - | - | 4,02 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Maravai LifeSciences Holdings Inc. Aktie
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.